Back to top
more

Iovance Biotherapeutics (IOVA)

(Delayed Data from NSDQ)

$11.64 USD

11.64
2,488,853

+0.10 (0.87%)

Updated Apr 26, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Does Iovance Biotherapeutics (IOVA) Have the Potential to Rally 49% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 49% upside potential for Iovance Biotherapeutics (IOVA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

HOOKIPA (HOOK), Merck Collaborate to Treat Head & Neck Cancers

by Zacks Equity Research

HOOKIPA (HOOK) collaborates with Merck (MRK) to evaluate the combination of its immunotherapy program, HB-200, with Merck's Keytruda for advanced head and neck squamous cell carcinoma.

Implied Volatility Surging for Iovance (IOVA) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Iovance (IOVA) stock based on the movements in the options market lately.

Iovance (IOVA) Q2 Earnings Miss Estimates, Pipeline in Focus

by Zacks Equity Research

Iovance's (IOVA) second-quarter loss is wider than expected. The company is progressing well in terms of development of its pipeline candidates.

Iovance (IOVA) Announces Lung Cancer Study Data on TIL Therapy

by Zacks Equity Research

Iovance (IOVA) is developing several TIL therapies, including LN-145, in a mid-stage study. Data from the lung cancer cohort evaluating LN-145 monotherapy demonstrates an ORR of 21.4%.

Iovance (IOVA) Falls on Negative Lifileucel Regulatory Update

by Zacks Equity Research

Iovance (IOVA) announces delay in BLA submission for its lead pipeline candidate, lifileucel for metastatic melanoma due to potency assay issue.

Is the Options Market Predicting a Spike in Iovance Biotherapeutics (IOVA) Stock?

by Zacks Equity Research

Investors need to pay close attention to Iovance Biotherapeutics (IOVA) stock based on the movements in the options market lately.

    Iovance (IOVA) Q1 Earnings Miss Estimates, Pipeline in Focus

    by Zacks Equity Research

    Iovance's (IOVA) first-quarter earnings lag estimates. The company is progressing well in terms of development of its lead pipeline candidate.

    Why Is Iovance Biotherapeutics (IOVA) Down 21.5% Since Last Earnings Report?

    by Zacks Equity Research

    Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Iovance (IOVA) Q4 Earnings Miss Estimates, Pipeline in Focus

    by Zacks Equity Research

    Iovance's (IOVA) fourth-quarter earnings miss estimates. The company is progressing well with development of its lead pipeline candidate.

    Why Is Iovance Biotherapeutics (IOVA) Up 6.7% Since Last Earnings Report?

    by Zacks Equity Research

    Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Iovance (IOVA) Q3 Earnings Beat Estimates, Pipeline in Focus

    by Zacks Equity Research

    Iovance's (IOVA) third-quarter earnings beat estimates. The company is progressing well with development of its lead pipeline candidate.

    Iovance Stock Down on Delay in Filing for Melanoma Candidate

    by Zacks Equity Research

    Iovance (IOVA) delays its application to the FDA for a tumor-infiltrating lymphocyte (TIL) therapy, lifileucel, for the treatment of metastaic melanoma until later in 2021.

    Iovance Biotherapeutics (IOVA) Down 1.6% Since Last Earnings Report: Can It Rebound?

    by Zacks Equity Research

    Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Iovance (IOVA) Q2 Earnings Beat Estimates, Pipeline in Focus

    by Zacks Equity Research

    Iovance's (IOVA) second-quarter bottom line beats estimates. The company is progressing well with its lead pipeline candidates.

    Why Is Iovance Biotherapeutics (IOVA) Down 1.4% Since Last Earnings Report?

    by Zacks Equity Research

    Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Iovance Biotherapeutics (IOVA) Upgraded to Buy: Here's What You Should Know

    by Zacks Equity Research

    Iovance Biotherapeutics (IOVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

    Iovance (IOVA) Q1 Loss Wider Than Expected, Revenues Nil

    by Zacks Equity Research

    Iovance's (IOVA) first-quarter loss wider than estimated. The company progressing well with its lead pipeline candidates.

    Sweta Killa headshot

    First-Mover Pandemic Disease Fight ETF On The Way

    by Sweta Killa

    Pacer Financial has filed for Pacer BioThreat ETF to enjoy the first-mover advantage that provide investors an option to capitalize on the new opportunities triggered by coronavirus.

    Do Options Traders Know Something About Iovance Biotherapeutics (IOVA) Stock We Don't?

    by Zacks Equity Research

    Investors need to pay close attention to Iovance Biotherapeutics (IOVA) stock based on the movements in the options market lately.

    Are Options Traders Betting on a Big Move in Iovance Biotherapeutics (IOVA) Stock?

    by Zacks Equity Research

    Investors need to pay close attention to Iovance Biotherapeutics (IOVA) stock based on the movements in the options market lately.

    Neena Mishra headshot

    Cancer-Fighting Stocks & ETF: What You Need to Know

    by Neena Mishra

    Many biotech stocks soared after they presented very promising cancer treatment results at the ASCO conference

    Neena Mishra headshot

    Why Cancer-Fighting Stocks & ETFs Are Soaring

    by Neena Mishra

    The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.

    Implied Volatility Surging for Iovance Biotherapeutics (IOVA) Stock Options

    by Zacks Equity Research

    Investors need to pay close attention to Iovance Biotherapeutics (IOVA) stock based on the movements in the options market lately.

    Are Options Traders Betting on a Big Move in Lion Biotechnologies (IOVA) Stock?

    by Zacks Equity Research

    Investors need to pay close attention to Lion Biotechnologies (IOVA) stock based on the movements in the options market lately.